Endoscopic surveillance for premalignant esophageal lesions: A community-based multicenter, prospective cohort study

He Li,Shaokai Zhang,Jinyi Zhou,Feng Tong,Jiyong Gong,Zhenqiu Zha,Ni Li,Changfa Xia,Jiang Li,Liyang Zheng,Pengfei Luo,Renqing Han,Hengmin Ma,Yili Lv,Hongmei Zeng,Rongshou Zheng,Maomao Cao,Fan Yang,Xinxin Yan,Dianqin Sun,Siyi He,Shaoli Zhang,Wanqing Chen,Jie He
DOI: https://doi.org/10.1016/j.cgh.2022.04.039
IF: 13.576
2022-05-26
Clinical Gastroenterology and Hepatology
Abstract:Background and Aims Mild and moderate dysplasia are major premalignant lesions of esophageal squamous cell carcinoma (ESCC); however, evidence of the progression risk in patients with these conditions is extremely limited. We aimed to assess the incidence and risk factors for advanced neoplasia in patients with mild-moderate dysplasia. Methods This prospective cohort study included patients with mild-moderate dysplasia from nine regions in rural China. These patients were identified from a community-based ESCC screening program conducted between 2010 and 2016 and were offered endoscopic surveillance until December 2021. We estimated the incidence of advanced esophageal neoplasia, including severe dysplasia, carcinoma in situ or ESCC, and identified potential risk factors using the Cox regression model. Results The 1183 patients with mild-moderate dysplasia were followed over a period of 6.95 years. During follow-up, 88 patients progressed to advanced neoplasia (7.44%), with an incidence rate of 10.44 per 1000 person-years. The median interval from the progression of mild-moderate dysplasia to advanced neoplasia was 2.39 years [interquartile range (IQR): 1.58-4.32]. A total of 74.47% of patients with mild-moderate dysplasia experienced regression to non-dysplasia, and 18.09% showed no lesion progression. Patients with mild-moderate dysplasia who had a family history of esophageal cancer and were ≥55 years old exhibited 97% higher advanced neoplasia yields than all patients with mild-moderate dysplasia. Conclusion In a country with a high incidence of ESCC, patients with mild-moderate dysplasia showed an overall risk of advanced neoplasia progression of 1.04% per year. Patients with mild-moderate dysplasia would be recommended for endoscopic surveillance during the first 2-3 years.
gastroenterology & hepatology
What problem does this paper attempt to address?